APA House Call: The Lack of Prevention, Screening in Psychiatry

Article

Why the field lacks behind in effective diagnostic tools, which could better inform tailored therapy.

The 2020 American Psychiatric Association (APA) Annual Meeting was cancelled this year, with plans made to convert the world-leading psychiatry conference into a two-part virtual session and educational platform for attendees.

In lieu of regular on-site coverage, HCPLive® will be running a series of interviews, insights, and reporting on topics that frequently headline the APA meeting—featuring familiar experts.

What can change the spectrum of care for any disease is a chain of breakthroughs—from perfecting screening, to understanding disease pathology, to accurate and timely diagnosis, and finally to individualized care. Each of these, in succession, often feed into one another: the clinician with confidence in identifying the problem quickly and completely can provide optimized care.

There’s expressed concern from at least a few experts that psychiatry has lacked these clinical breakthroughs for some time.

Carsten Korth, MD, a professor of molecular and neuropathology with the University of Dusseldorf, discussed with HCPLive his doubt that molecular-based testing for psychiatric diseases would be widely accepted in psychiatry.

“They don’t want to be guided by machines or molecules in this century-old tradition of weighing clinical symptoms,” Korth explained.

Korth talked to HCPLive about his and his colleagues’ notion that the gap from clinical schizophrenia diagnosis to blood-based testing can only be cleared with compromise. The argument is one worth having, he claimed.

“It’s really remarkable how there is so little progress in clinical psychiatry compared to neurology,” he said. “Psychiatry is still using drugs that were invented 70 years ago. Very clearly, you can’t give good therapy without good biologic diagnostics.”

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
© 2024 MJH Life Sciences

All rights reserved.